ATHXQ.US Athersys, Inc.

Healthcare Biotechnology USA Stocks
0.0000 USD
Close of Nov 14, 2026
Market cap
USD 617.00
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Sep 2023.

Is ATHXQ.US undervalued?

Graham number

The Graham number of Athersys, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Athersys, Inc. fundamental analysis

No fundamental analysis for Athersys, Inc. yet.

Athersys, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Athersys, Inc.

Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition…

Full company profile